TAK Q1 2017 Earnings Report — Takeda Pharmaceutical Company Limited Revenue & Financial Results | Market Cap Arena

Takeda Pharmaceutical Company LimitedTAK

Q1 2017 Earnings

Reported June 29, 2017

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	Q1 2017	Q4 2016	Q1 2016	QoQ Change	YoY Change
Revenue	$2.8B	—	—	—	—
Op. Income	$1.2B	—	—	—	—
Gross Margin	73.0%	—	—	—	—
Net Margin	32.3%	—	—	—	—
EPS (Diluted)	$0.58	—	—	—	—
Free Cash Flow	$294M	—	—	—	—

Revenue Flow

Item	Amount
REVENUE	$2.8B
Cost of Revenue	$757M
GROSS PROFIT	$2.1B
R&D Expenses	$474M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$914M
Other Expenses	-$559M
Operating Expenses	$829M
Cost & Expenses	$1.6B
OPERATING INCOME	$1.2B
Interest Income	$85M
Interest Expense	$62M
Other Income/Expenses	$20M
INCOME BEFORE TAX	$1.2B
Income Tax Expense	$334M
Net Income from Continuing Ops	$908M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$907M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$907M
D&A	$288M
EBIT	$1.3B
EBITDA	$1.6B
EPS	$1
EPS Diluted	$1

Income Statement

Item	Amount
REVENUE	$2.8B
Cost of Revenue	$757M
GROSS PROFIT	$2.1B
R&D Expenses	$474M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$914M
Other Expenses	-$559M
Operating Expenses	$829M
Cost & Expenses	$1.6B
OPERATING INCOME	$1.2B
Interest Income	$85M
Interest Expense	$62M
Other Income/Expenses	$20M
INCOME BEFORE TAX	$1.2B
Income Tax Expense	$334M
Net Income from Continuing Ops	$908M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$907M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$907M
D&A	$288M
EBIT	$1.3B
EBITDA	$1.6B
EPS	$1
EPS Diluted	$1

Cash Flow Statement

Item	Amount
Net Income	$908M
Depreciation & Amortization	$288M
Stock-Based Compensation	$0
Deferred Income Tax	$334M
Other Non-Cash Items	$120M
Change in Working Capital	-$278M
OPERATING CASH FLOW	$467M
Capital Expenditure	-$173M
Acquisitions (Net)	$520M
Purchases of Investments	$157M
Sales/Maturities of Investments	$71M
Other Investing Activities	$48M
NET CASH FROM INVESTING	$622M
Net Debt Issuance	-$24M
Common Stock Repurchased	-$117M
Common Dividends Paid	-$398M
Other Financing Activities	-$2M
NET CASH FROM FINANCING	-$550M
FREE CASH FLOW	$294M
Net Change in Cash	$570M

Balance Sheet

Item	Amount
Cash & Equivalents	$2.7B
Short-Term Investments	$363M
Net Receivables	$3.0B
Inventory	$1.5B
Other Current Assets	$468M
TOTAL CURRENT ASSETS	$8.0B
PP&E (Net)	$3.3B
Goodwill	$6.6B
Intangible Assets	$6.6B
Long-Term Investments	$1.9B
Tax Assets	$509M
Other Non-Current Assets	$342M
TOTAL NON-CURRENT ASSETS	$19.3B
TOTAL ASSETS	$27.2B
Account Payables	$1.4B
Short-Term Debt	$1.3B
Deferred Revenue	$0
Other Current Liabilities	$2.7B
TOTAL CURRENT LIABILITIES	$5.9B
Long-Term Debt	$5.9B
Deferred Revenue NC	$0
Deferred Tax Liabilities	$980M
Other Non-Current Liabilities	$1.7B
TOTAL NON-CURRENT LIABILITIES	$8.6B
TOTAL LIABILITIES	$14.5B
Common Stock	$815M
Additional Paid-In Capital	$403M
Retained Earnings	$9.9B
Treasury Stock	-$327M
Accum. Other Comp. Income	$2.2B
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$12.6B
Minority Interest	$139M
TOTAL EQUITY	$12.8B
TOTAL LIABILITIES & EQUITY	$27.2B
Total Debt	$7.2B
Net Debt	$4.5B